Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/90242
Название: Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice
Авторы: de, Munter, J. P. J. M.
Shafarevich, I.
Liundup, A.
Pavlov, D.
Wolters, E. C.
Gorlova, A.
Veniaminova, E.
Umriukhin, A.
Kalueff, A.
Svistunov, A.
Kramer, B. W.
Lesch, K. -P.
Strekalova, T.
Дата публикации: 2020
Издатель: Blackwell Publishing Ltd
Библиографическое описание: Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice / J. P. J. M. de Munter, I. Shafarevich, A. Liundup, D. Pavlov, et al. . — DOI 10.1111/cns.13280 // CNS Neuroscience and Therapeutics. — 2020. — Vol. 5. — Iss. 26. — P. 504-517.
Аннотация: Aims: Mutations in DNA/RNA-binding factor (fused-in-sarcoma) FUS and superoxide dismutase-1 (SOD-1) cause amyotrophic lateral sclerosis (ALS). They were reproduced in SOD-1-G93A (SOD-1) and new FUS[1-359]-transgenic (FUS-tg) mice, where inflammation contributes to disease progression. The effects of standard disease therapy and anti-inflammatory treatments were investigated using these mutants. Methods: FUS-tg mice or controls received either vehicle, or standard ALS treatment riluzole (8 mg/kg/day), or anti-inflammatory drug a selective blocker of cyclooxygenase-2 celecoxib (30 mg/kg/day) for six weeks, or a single intracerebroventricular (i.c.v.) infusion of Neuro-Cells (a preparation of 1.39 × 106 mesenchymal and hemopoietic human stem cells, containing 5 × 105 of CD34+ cells), which showed anti-inflammatory properties. SOD-1 mice received i.c.v.-administration of Neuro-Cells or vehicle. Results: All FUS-tg-treated animals displayed less marked reductions in weight gain, food/water intake, and motor deficits than FUS-tg-vehicle-treated mice. Neuro-Cell-treated mutants had reduced muscle atrophy and lumbar motor neuron degeneration. This group but not celecoxib-FUS-tg-treated mice had ameliorated motor performance and lumbar expression of microglial activation marker, ionized calcium-binding adapter molecule-1 (Iba-1), and glycogen-synthase-kinase-3ß (GSK-3ß). The Neuro-Cells-treated-SOD-1 mice showed better motor functions than vehicle-treated-SOD-1 group. Conclusion: The neuropathology in FUS-tg mice is sensitive to standard ALS treatments and Neuro-Cells infusion. The latter improves motor outcomes in two ALS models possibly by suppressing microglial activation. © 2019 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd
Ключевые слова: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
FUSED IN SARCOMA (FUS) PROTEIN
GLYCOGEN-SYNTHASE KINASE-3ß (GSK-3ß)
MICROGLIA ACTIVATION
MOUSE
STEM CELL THERAPY
SUPEROXIDE DISMUTASE-1 (SOD-1) G93A MICE
CELECOXIB
CELL MARKER
COPPER ZINC SUPEROXIDE DISMUTASE
GLYCOGEN SYNTHASE KINASE 3BETA
IONIZED CALCIUM BINDING ADAPTER MOLECULE 1
RILUZOLE
UNCLASSIFIED DRUG
AMYOTROPHIC LATERAL SCLEROSIS
ANIMAL EXPERIMENT
ANIMAL MODEL
ANIMAL TISSUE
ARTICLE
BODY WEIGHT GAIN
CONTROLLED STUDY
DISEASE EXACERBATION
DRUG EFFECT
EXPERIMENTAL NEUROLOGIC DISEASE
FLUID INTAKE
GENE MUTATION
HEMATOPOIETIC STEM CELL
HUMAN
HUMAN CELL
INFLAMMATION
MALE
MESENCHYMAL STEM CELL
MOTOR PERFORMANCE
MOUSE
MSOD1 MOUSE
MUSCLE ATROPHY
NERVE CELL DEGENERATION
NONHUMAN
PILOT STUDY
STEM CELL TRANSPLANTATION
TRANSGENIC MOUSE
URI: http://elar.urfu.ru/handle/10995/90242
Условия доступа: info:eu-repo/semantics/openAccess
cc-by
Идентификатор SCOPUS: 85076897663
Идентификатор WOS: 000503855500001
Идентификатор PURE: 12657001
ISSN: 1755-5930
DOI: 10.1111/cns.13280
Сведения о поддержке: We thank ?5-100? Russian Excellence Program, Prof. Daniel C. Anthony, Diana Babayevskaya, and Arina Kosakova for their highly valuable contribution. ?Neuro-Cells? preparation was provided by Neuroplast BV, Maastricht, Netherlands.
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
10.1111-cns.13280.pdf2,06 MBAdobe PDFПросмотреть/Открыть


Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.